AAAAAA
Results:
1-7
|
Results: 7
Authors:
ALEXANDER ACM
AKERS A
MATZKE GR
AWEEKA FT
FRALEY DS
Citation: Acm. Alexander et al., DISPOSITION OF FOSCARNET DURING PERITONEAL-DIALYSIS, The Annals of pharmacotherapy, 30(10), 1996, pp. 1106-1109
Authors:
MATZKE GR
FRYE RF
ALEXANDER ACM
REYNOLDS R
DIXON R
JOHNSTON J
RAULT RM
Citation: Gr. Matzke et al., THE EFFECT OF RENAL-INSUFFICIENCY AND HEMODIALYSIS ON THE PHARMACOKINETICS OF NALMEFENE, Journal of clinical pharmacology, 36(2), 1996, pp. 144-151
Authors:
ALEXANDER ACM
MATZKE GR
FRYE RF
BRUNS F
RAULT R
Citation: Acm. Alexander et al., DIFFERENTIAL RESPONSE OF SERUM IRON INDEXES (SII) TO IRON DEXTRAN (ID) IN HEMODIALYSIS-PATIENTS, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 104-104
Authors:
FRYE RF
MATZKE GR
ALEXANDER ACM
PALEVSKY P
RAULT R
BRANCH RA
Citation: Rf. Frye et al., EFFECT OF RENAL-INSUFFICIENCY ON CYP ACTIVITY, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 105-105
Authors:
CLEARY DJ
MATZKE GR
ALEXANDER ACM
JOY MS
Citation: Dj. Cleary et al., MEDICATION KNOWLEDGE AND COMPLIANCE AMONG PATIENTS RECEIVING LONG-TERM DIALYSIS, American journal of health-system pharmacy, 52(17), 1995, pp. 1895-1900
Authors:
MATZKE GR
ALEXANDER ACM
FRYE RF
REYNOLDS R
WHITMAN C
DIXON RB
RAULT R
Citation: Gr. Matzke et al., THE DISPOSITION OF NALMEFENE IS SIGNIFICANTLY ALTERED IN PATIENTS WITH END-STAGE RENAL-DISEASE, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 218-218
Authors:
ALEXANDER ACM
MATZKE GR
RAULT R
Citation: Acm. Alexander et al., INDIVIDUALIZED DOSING OF INTRAVENOUS IRON DEXTRAN FOR CHRONIC-HEMODIALYSIS PATIENTS, Journal of the American Society of Nephrology, 5(3), 1994, pp. 430-430
Risultati:
1-7
|